Skip to main content
. Author manuscript; available in PMC: 2008 May 10.
Published in final edited form as: Vaccine. 2007 Feb 15;25(19):3841–3850. doi: 10.1016/j.vaccine.2007.01.107

Fig. 1.

Fig. 1

Incorporation of wild type and mutant HIV Env into VLPs. Quantitative estimation of Env in VLPs was performed using an ELISA. Gag: HIV Env-negative SIV Gag VLPs, WT: SHIV VLPs with wild type HIV Env 89.6, dV1V2: SHIV VLPs with dV1V2 mutant HIV Env, 3G: SHIV VLPs with 3G mutant HIV Env, 3G-dV2−1G: SHIV VLPs with 3G-dV2−1G mutant HIV Env.